Basal studies and preclinical evaluations of newly developed antifungal agents.

Yamaguchi, Hideyo

doi:10.3314/jjmm1960.26.116

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the bioavailability of itraconazole varies greatly, and drug resistance to FLU develops readily [ 30 ]. In contrast, the newer triazoles such as voriconazole and posaconazole show a broader antibacterial spectrum, higher bioavailability, and significantly fewer adverse reactions than the first-generation triazole drugs [ 31 ]. Echinocandins such as micafungin target 1,3-β-D glucan synthase, inhibit the synthesis of glucan synthase, and interrupt formation of the cell wall, ultimately leading to cell death [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy and safety of antifungal drugs for the treatment of Candida parapsilosis infections: a systematic review and network meta-analysis

Qin

Shan

Jiang

et al. 2021

Journal of Medical Microbiology

View full text Add to dashboard Cite

Antifungal drugs have already been established as an effective treatment option for Candida parapsilosis infections, but there is no universal consensus on the ideal target for clinical efficacy and safety of antifungal drugs for the treatment of C. parapsilosis infections. Few studies have directly compared the efficacies of antifungal drugs for the treatment of C. parapsilosis infections. We hypothesize that different antifungal drugs offer differing clinical efficacy and safety for the treatment of C. parapsilosis infections. We performed a comprehensive network meta-analysis on different strategies for C. parapsilosis infection treatment and compared the clinical efficacy and safety of antifungal drugs as interventions for C. parapsilosis infections. The Cochrane Database of Systematic Reviews, Medline, Embase, PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), Technology of Chongqing VIP database, Wan Fang Data, and SinoMed databases were searched to identify appropriate randomized trials. Among the extracted C. parapsilosis cases, the survival and death rates with treatment of C. parapsilosis infection were compared among groups treated with different antifungal drugs. According to the evidence-network analysis, echinocandins were a better choice than other drugs for treating C. parapsilosis infections, and more importantly, caspofungin showed a more preferable effect for decreasing the risk of 30 day mortality. In conclusion, this study systematically evaluated the effectiveness and safety of antifungal drugs for the purpose of helping clinicians choose the most appropriate antifungal drugs. Future studies with larger samples are needed to evaluate the effects of patient factors on the clinical efficacy and safety of antifungal drugs for C. parapsilosis infections.

show abstract

Section: Discussionmentioning

confidence: 99%